IC20 Rec'd PCT/PTO 2 1 SEP 2009

FILING BY "EXPRESS MAIL"

Express Mail Label Number

September 21,2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

SHUA-HAIM ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP04/003418

FILED: 31 MARCH 2004

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: USE OF CARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF

AGITATION IN DEMENTIA PATIENTS

MS: Amendment Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP04/003418, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis

Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080

(862) 778-7960

Date: 21 Sep. 2005

Respectfully submitted

Edward J. Wilusz Jr. Attorney for Applicants

Reg. No. 52,370

FORM PTO-1449 (REV. 7-85)

EXAMINER

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 2
ATTY. DOCKET NO.
PN/4-32146A
APPLICANT
SHUA-HAIM ET AL.
FILING DATE

Group

JC20 Rec'd PCT/PTO 31 SEP 2005

U.S. PATENT DOCUMENTS EXAMINER INITIAL **FILING DATE DOCUMENT NUMBER** DATE NAME CLASS **SUBCLASS** AΑ AB AC AD AΕ AF AG AΗ ΑI ΑJ AK AL **FOREIGN PATENT DOCUMENTS** TRANSLATION YES NO **CLASS** SUBCLASS **OFFICE DOCUMENT NUMBER** DATE **EPO** 1/2/97 AM EP 0 751 129 П ΑN AO ΑP AQ OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Ambrosio A F Et Al: "Mechanisms Of Action Of Carbamazepine And Its Derivatives, Oxcarbazepine, Bia 2-093, And Bia 2-024" Neurochemical Research, Plenum Press, New York, Us, Vol. 27, No. 1/2, AR February 2002 Benes J ET AL: "Anticonvulsant And Sodium Channel-Blocking Properties Of Novel 10,11-Dihydro-5H-Dibenzäb.Füazepine-5-Carb Oxamide Derivatives" Journal Of Medicinal Chemistry, American AS Chemical Society. Washington, US, vol. 42, 1999, pages 2582-2587, XP002206156 ISSN: 0022-Lemke Matthias R: "Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics" Journal Of Clinical Psychiatry, vol. 56, no. 8, 1995, pages 354-357, XP000903495 ISSN: AT 0160-6689

DATE CONSIDERED

^{*}EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449 (REV. 7-85) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 2
ATTY. DOCKET NO.
PN/4-33146A
APPEICATION NO.
NO. West Assigned 380
RPPTICANT
SHUA-HAIM ET AL.

JC20 Rec'd PCT/PTO 21 SEP 2005

EXAMINER INITIAL OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.) Fitzgerald Brian J et al: "Elevation Of Carbamazepine-10,11- Epoxide By Quetiapine." Pharmacotherapy, Vol. 22, No. 11, November 2002 (2002-11), Pages 1500-1503, XP009033502 DA ISSN: 0277-0008 SHUA-HAIM J: "Oxcarbazepine in the management of behavioral agitation in community-dwelling patients with Alzheimer's disease: An open-label Study." European DB Neuropsychopharmacology, vol. 13, no. Supplement 4, September 2003 (2003-09), page S434, XP002288071 & 16TH Congress Of The European College Of Neuropsychopharmacology; Prague, Czech Republic; September 20-24, 2003 ISSN: 0924-977X DC DD DE DF DG DH DI DJ DK DL DM DΝ **DATE CONSIDERED EXAMINER**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.